Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

A once-a-day pill health experts are calling 'life-changing' will be offered to hundreds of people living with cystic ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.